Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial
暂无分享,去创建一个
Y. Kurihara | H. Miyoshi | T. Atsumi | A. Nakamura | Kazuno Omori | S. Aoki | K. Cho | Takahiro Takase | Aika Miya | N. Manda | A. Miya | T. Takase